🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT05028686
Recruiting Observational

Predicting Readmissions Using Omics, Biostatistical Evaluate and Artificial Intelligence

NCT05028686 · tracked via the Priya Life Science Canada tracker
Sponsor
Institute for Clinical Evaluative Sciences
Phase
Observational
Started
2019-02-01
Last updated
2021-09-02

Condition(s) studied

Heart Failure

Investigational drug(s) / intervention(s)

No intervention

No intervention: Observational cohort

Study summary

This study is a prospective registry that aims to predict readmissions in patients with heart failure, using -omics, machine learning, patient reported outcomes, clinical data and other high-dimensional data sources.

Eligibility

Sex
ALL
Min age
18 Years
Max age
105 Years
Healthy volunteers
No
Inclusion Criteria: * Any patient aged 18 years or older admitted to hospital or seen in the emergency department with heart failure defined clinically * The diagnosis will be guided by the Framingham criteria for HF and/or BNP. A BNP \>400 will be defined as definite heart failure and BNP 100-400 classified as possible heart failure. * Provides informed consent Exclusion Criteria: * Patients who cannot communicate due to dementia or severe cognitive deficits * non-Ontario residents * nursing home residents * those who are not discharged home but are discharged to a skilled nursing facility (long-term care or chronic institution) * those who are unable to communicate who do not have a proxy (e.g. spouse or close family member) to facilitate communication with the patient.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Health Network Toronto Ontario Recruiting

More Institute for Clinical Evaluative Sciences trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05028686 on ClinicalTrials.gov ↗ ← All trials in Canada